2022
Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N, Hui P. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma. Archives Of Pathology & Laboratory Medicine 2022, 146: 0. PMID: 35687792, DOI: 10.5858/arpa.2021-0547-oa.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaClinical trial criteriaHER2 gene amplificationTrial criteriaHER2 immunohistochemistrySerous carcinomaAnti-human epidermal growth factor receptor 2 (HER2) therapyClinical Oncology/CollegeHER2 testing algorithmHER2 FISHProspective clinical investigationHER2 IHC 2HER2/CEP17Gene amplificationContext of breastTherapeutic responseIHC 2HER2 amplificationAverage HER2Most tumorsClinical investigationImmunohistochemistryHER2 fluorescenceTumorsMonosomy 17
2017
Hormone producing gynecological tumors: pathologic entities and clinical significance
Boto AN, Hui P. Hormone producing gynecological tumors: pathologic entities and clinical significance. Expert Review Of Endocrinology & Metabolism 2017, 13: 9-24. PMID: 30063444, DOI: 10.1080/17446651.2018.1411799.Peer-Reviewed Original ResearchConceptsHormonal biomarkersGynecologic tumorsGynecologic neoplasmsOverproduction of hormonesAbnormal clinical manifestationsPatient treatment optionsGynecological organsNormal physiological settingsSerum hormonesClinical manifestationsGynecological tumorsTreatment optionsAbnormal elevationPathologic entityPathological diagnosisTherapeutic responseDisease progressionClinical significanceClinical utilityTreatment efficacyClinical monitoringHormonal productionHormonal productsTumorsHormone